SUNPHARMA.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 12:59):

Stats
Объем за сегодня	1.24M
Средний объем	2.75M
Рыночная капитализация	3 668.86B
EPS	INR10.50 ( 2024-01-31 )
Дата следующего отчета о доходах	( INR6.83 ) 2024-05-24
Last Dividend	INR4.00 ( 2023-07-28 )
Next Dividend	INR0 ( N/A )
P/E	41.14
ATR14	INR1.359 (0.09%)

Объем Корреляция

Длинно: 0.60 (weak)

Кратко: -0.49 (neutral)

Signal:(53.771) Neutral

Sun Pharmaceutical Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Sun Pharmaceutical Корреляция - Валюта/Сырье

0.86
( strong )

0.78
( moderate )

0.91
( very strong )

0.76
( moderate )

0.06
( neutral )

0.22
( neutral )

Sun Pharmaceutical Финансовые показатели

Annual	2022
Выручка:	INR432.79B
Валовая прибыль:	INR326.17B (75.36 %)
EPS:	INR35.32

FY	2022
Выручка:	INR432.79B
Валовая прибыль:	INR326.17B (75.36 %)
EPS:	INR35.32

FY	2022
Выручка:	INR384.26B
Валовая прибыль:	INR267.19B (69.53 %)
EPS:	INR13.60

FY	2021
Выручка:	INR334.98B
Валовая прибыль:	INR236.13B (70.49 %)
EPS:	INR12.10

Financial Reports:

No articles found.

Sun Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR3.00 (N/A)	INR0 (N/A)	INR7.50 (N/A)	INR0 (N/A)	INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Sun Pharmaceutical Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.54 - low (17.82%) | Divividend Growth Potential Score: 4.46 - Stable (10.74%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.0208	1996-06-24
Last Dividend	INR4.00	2023-07-28
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	33	--
Total Paid Out	INR59.60	--
Avg. Dividend % Per Year	0.77%	--
Score	2.84	--
Div. Sustainability Score	3.54
Div.Growth Potential Score	4.46
Div. Directional Score	4.00	--

Next Divdend (Est)
(2024-06-03)

INR4.08 Estimate 6.47 %

Dividend Stability

0.26 Very Poor

Dividend Score

2.84

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1996	INR0	0.00%
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.39%
2019	INR2.75	0.63%
2020	INR4.00	0.92%
2021	INR7.50	1.26%
2022	INR10.00	1.18%
2023	INR11.50	1.15%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUNPHARMA.NS	Dividend Junior	2023-07-28	Semi-Annually	29	0.77%
NAVA.NS	Dividend Knight	2023-07-24	Annually	23	2.35%
HONAUT.NS	Dividend Junior	2023-08-03	Annually	21	0.15%
CARBORUNIV.NS	Dividend Knight	2023-07-25	Semi-Annually	23	0.33%
ROHLTD.NS	Dividend Junior	2023-09-15	Sporadic	19	0.20%
LAURUSLABS.NS	Dividend Knight	2023-05-10	Semi-Annually	8	0.35%
FOSECOIND.NS	Dividend Knight	2023-05-17	Annually	22	0.68%
APOLLO.NS	Dividend Junior	2023-09-22	Annually	7	0.79%
TCI.NS	Dividend Junior	2023-07-25	Semi-Annually	23	0.70%
OBEROIRLTY.NS	Dividend Junior	2023-06-21	Sporadic	14	0.19%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.191	1.500	6.18	9.28	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.149	1.500	9.45	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	43.19	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	21.49	2.00	2.84	5.67	[0 - 30]
freeCashFlowPerShareTTM	21.49	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.774	1.000	0.428	0.428	[0.2 - 0.8]
operatingProfitMarginTTM	0.238	1.000	7.23	7.23	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	40.89	1.000	5.97	0	[1 - 100]
returnOnEquityTTM	0.149	2.50	9.65	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	21.49	2.00	2.84	10.00	[0 - 30]
dividendYielPercentageTTM	0.824	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	21.49	2.00	2.84	5.67	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.257	1.500	-1.618	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.110	1.000	9.74	0	[0.1 - 0.5]
Total Score				4.46

Sun Pharmaceutical

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.